December 27, 2005
Gilead to Repatriate Funds to the United States

December 15, 2005
Dr. George P. Shultz Resigns from Gilead Sciences Board of Directors

December 13, 2005
John W. Madigan Joins Gilead Sciences Board of Directors

December 12, 2005
Data Show Efficacy of Standard Dosing Regimen of AmBisome(R) is Similar to High Loading Dose for Patients with Invasive Fungal Infections

December 6, 2005
Gilead Launches an Educational Website on Advances in Combination Therapy For HIV

December 2, 2005
Gilead Sciences to Present at the NASDAQ 16th Investor Program on Thursday, December 8th; Webcast Available Through Gilead Corporate Website

November 28, 2005
Gilead Sciences to Present at the Lazard Capital Markets Life Sciences Conference on Wednesday, November 30th; Webcast Available Through Gilead Corporate Website

November 17, 2005
Preliminary 24-Week Data Evaluating the Impact of Switching from Twice-Daily Combivir^® to Once-Daily Truvada^® in Patients with HIV Presented at 10th European AIDS Conference

November 16, 2005
Gilead and Roche End Tamiflu^® Dispute; Expanded Collaboration Includes Gilead Role in Oversight of Manufacturing and Commercialization

November 14, 2005
Five-Year Data Evaluating Long-Term Therapy with Hepsera(R) for Hepatitis B ''e'' Antigen-Negative Chronic Hepatitis B Presented at AASLD Annual Meeting

November 11, 2005
Gilead Sciences to Present at the Credit Suisse First Boston Healthcare Conference on Thursday, November 17th; Webcast Available Through Gilead Corporate Website

November 4, 2005
Gilead Sciences to Present at the CIBC World Markets 16th Annual Healthcare Conference on Monday, November 7th; Webcast Available Through Gilead Corporate Website

October 18, 2005
Gilead Sciences Announces Third Quarter 2005 Financial Results

October 11, 2005
Gilead Sciences to Release Third Quarter 2005 Financial Results on Tuesday, October 18, 2005; Conference Call and Webcast to Follow

September 23, 2005
Gilead Sciences to Present at the 2005 UBS Global Life Sciences Conference on Tuesday, September 27th; Webcast Available Through Gilead Corporate Website

September 2, 2005
Gilead Sciences to Present at Two Upcoming Investor Conferences

August 29, 2005
Gilead Reduces Prices for Viread^® and Truvada^® in the Developing World

August 18, 2005
Gilead Sciences' Board Member Amends Existing Rule 10b5-1 Stock Trading Plan

August 15, 2005
Gilead and Achillion Announce Initiation of Phase I Clinical Trial Evaluating GS 9132 for the Treatment of Hepatitis C

August 9, 2005
Gilead Provides Update on Development of Fixed-Dose Regimen of Truvada^® (Emtricitabine and Tenofovir Disoproxil Fumarate) and Sustiva^® (Efavirenz)

July 28, 2005
Gilead Sciences Announces Management Promotions

July 27, 2005
John F. Cogan Joins Gilead Sciences Board of Directors

July 22, 2005
Gilead Sciences and Royalty Pharma Complete $525 Million Purchase from Emory University of Emtricitabine Royalty Interest

July 19, 2005
Gilead Sciences Announces Initiation of Phase III Clinical Program Evaluating Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B Virus

July 19, 2005
Gilead Sciences Announces Second Quarter 2005 Financial Results

July 18, 2005
Gilead Sciences and Royalty Pharma Announce $525 Million Agreement with Emory University to Purchase Royalty Interest for Emtricitabine

July 12, 2005
Gilead Sciences to Release Second Quarter 2005 Financial Results on Tuesday, July 19, 2005; Conference Call and Webcast to Follow

June 29, 2005
Data Evaluating Long-Term Therapy with Hepsera for Hepatitis B ''e'' Antigen-Negative Chronic Hepatitis B Published in the New England Journal of Medicine

June 23, 2005
Gilead Delivers Termination Notice to Roche for Tamiflu Development and Licensing Agreement

June 21, 2005
Gilead Announces Initiation of Phase I/II Clinical Trial Evaluating HIV Integrase Inhibitor GS 9137

June 10, 2005
Gilead Sciences to Present at the Goldman Sachs 26th Annual Global Healthcare Conference on Wednesday, June 15th; Webcast Available Through Gilead Corporate Website

May 27, 2005
Gilead Sciences to Present at Two Upcoming Investor Conferences

May 13, 2005
Gilead Sciences to Present at the Banc of America Securities Health Care Conference 2005 on Tuesday, May 17th; Webcast Available Through Gilead Corporate Website

April 29, 2005
Gilead Sciences' Board Member Establishes Rule 10b5-1 Stock Trading Plan

April 26, 2005
Gilead Provides Update on Development of Fixed-Dose Regimen of Truvada (emtricitabine and tenofovir disoproxil fumarate) and Sustiva (efavirenz)

April 25, 2005
Gilead Sciences and Aspen Pharmacare Sign Letter of Intent to Establish Non-Exclusive Licensing and Distribution Agreement for Antiretrovirals Truvada and Viread in Developing World Countries

April 19, 2005
Gilead Sciences Announces First Quarter 2005 Financial Results

April 8, 2005
Gilead Sciences to Release First Quarter 2005 Financial Results on Tuesday, April 19, 2005; Conference Call and Webcast to Follow

April 4, 2005
Gilead Sciences Announces Early Termination of Hart-Scott-Rodino Waiting Period for the Japan Tobacco License for JTK-303

March 28, 2005
Gilead Sciences to Present at Two Upcoming Investor Conferences

March 22, 2005
Gilead and Japan Tobacco Sign Licensing Agreement for Novel HIV Integrase Inhibitor

March 16, 2005
Gilead Expands Global Access Program for HIV Therapies to Include Additional Countries in the Caribbean and Latin America; Bahamas Manufacturing Plant Established

March 11, 2005
Gilead Sciences to Present at the SG Cowen & Co. 25th Annual Health Care Conference on Tuesday, March 15th; Webcast Available Through Gilead Corporate Website

February 28, 2005
48-Week Data Comparing Viread Versus Abacavir as Replacement for Thymidine Analogue in Lipoatraphic HIV Patients Presented at the 12th Conference on Retroviruses and Opportunistic Infections

February 23, 2005
European Commission Approves Truvada, a Once-a-Day Tablet Containing Gilead Sciences' Anti-HIV Drugs Emtriva and Viread

February 4, 2005
Gilead Sciences to Present at the Merrill Lynch Global Pharmaceutical, Medical Device, and Biotechnology Conference on Tuesday, February 8th

February 3, 2005
Gilead Announces Preliminary 48-Week Data From Study 934 Comparing Viread and Emtriva to Combivir Both in Combination With Sustiva in Patients With HIV

January 27, 2005
Gilead Sciences Announces Fourth Quarter and Full Year 2004 Financial Results

January 21, 2005
Gilead Sciences to Release Fourth Quarter and Year End 2004 Financial Results on Thursday, January 27, 2005; Conference Call and Webcast to Follow

January 5, 2005
Gilead Sciences to Present at the 23rd Annual JPMorgan Healthcare Conference on Monday, January 10th; Webcast Available Through Gilead Corporate Website